• Je něco špatně v tomto záznamu ?

Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study

T. Fait, T. Baltazár, L. Bubenickova, J. Kestranek, M. Stepan, M. Muller, P. Turcan

. 2023 ; 12 (19) : . [pub] 20230927

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022819

INTRODUCTION: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity. AIM: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device. METHODS: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active-82 patients) vs. therapy with zero intensity (placebo-9 patients). RESULTS: A total of 91 subjects whose average age was 48.69 ± 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F1,574 = 46.91; p < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F1,278 = 7.97; p = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F1,384 = 15.51; p < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required. CONCLUSIONS: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022819
003      
CZ-PrNML
005      
20240116163141.0
007      
ta
008      
240105s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm12196234 $2 doi
035    __
$a (PubMed)37834879
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fait, Tomas $u Department of Obsterics and Gynaecology, 2nd Faculty of Medicine, Charles University, 150 00 Prague, Czech Republic $u Department of Health Care Studies, College of Polytechnics Jihlava, 586 01 Jihlava, Czech Republic $1 https://orcid.org/0000000228129274 $7 xx0053331
245    10
$a Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study / $c T. Fait, T. Baltazár, L. Bubenickova, J. Kestranek, M. Stepan, M. Muller, P. Turcan
520    9_
$a INTRODUCTION: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity. AIM: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device. METHODS: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active-82 patients) vs. therapy with zero intensity (placebo-9 patients). RESULTS: A total of 91 subjects whose average age was 48.69 ± 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F1,574 = 46.91; p < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F1,278 = 7.97; p = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F1,384 = 15.51; p < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required. CONCLUSIONS: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baltazár, Tivadar $u Department of Agrochemistry, Soil Science, Microbiology and Plant Nutrition, Faculty of AgriSciences, Mendel University in Brno, 613 00 Brno, Czech Republic
700    1_
$a Bubenickova, Leona $u Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0009000505363147
700    1_
$a Kestranek, Jan $u Department of Obsterics and Gynaecology, Hospital Trutnov, 541 01 Trutnov, Czech Republic $u Department of Obsterics and Gynaecology, Medical Faculty in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Stepan, Martin $u Department of Obsterics and Gynaecology, Medical Faculty in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Muller, Miroslav $u Gynedology Pardubice Muller, 530 02 Pardubice, Czech Republic
700    1_
$a Turcan, Pavel $u Mediol Centre-Olomouc, 779 00 Olomouc, Czech Republic
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 12, č. 19 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37834879 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163138 $b ABA008
999    __
$a ok $b bmc $g 2036407 $s 1209264
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 12 $c 19 $e 20230927 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
LZP    __
$a Pubmed-20240105

Najít záznam

Citační ukazatele

Možnosti archivace